Next Science Limited (NXS.AX)
- Previous Close
0.3150 - Open
0.3350 - Bid 0.3200 x 853200
- Ask 0.3450 x 1877300
- Day's Range
0.3200 - 0.3400 - 52 Week Range
0.1800 - 0.7000 - Volume
201,976 - Avg. Volume
138,035 - Market Cap (intraday)
99.176M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date Jul 25, 2024 - Jul 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.37
Next Science Limited engages in the research, development, and commercialization of technologies that address the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial gel that conforms to the postoperative wound; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.
www.nextscience.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: NXS.AX
Performance Overview: NXS.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NXS.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NXS.AX
Valuation Measures
Market Cap
99.18M
Enterprise Value
86.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.33
Price/Book (mrq)
5.03
Enterprise Value/Revenue
3.89
Enterprise Value/EBITDA
-5.99
Financial Highlights
Profitability and Income Statement
Profit Margin
-73.36%
Return on Assets (ttm)
-65.58%
Return on Equity (ttm)
-156.02%
Revenue (ttm)
22.18M
Net Income Avi to Common (ttm)
-16.27M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
9.28M
Total Debt/Equity (mrq)
7.50%
Levered Free Cash Flow (ttm)
-10.39M
Research Analysis: NXS.AX
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: NXS.AX
NXS.AX does not have Company Insights